Investigating how obesity affects severe COVID-19
SARS-CoV-2 Antibody-mediated Inflammatory Responses by Macrophages in Individuals With and Without Obesity
This study is trying to see how obesity affects the immune response and severity of COVID-19 by comparing blood samples from obese patients and non-obese healthcare workers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Franciscus Gasthuis Academic / other |
| Locations | 1 site (Rotterdam, South Holland) |
| Trial ID | NCT06968442 on ClinicalTrials.gov |
What this trial studies
This study examines the role of obesity in the pathophysiology of severe COVID-19 by comparing blood samples from obese patients eligible for bariatric surgery with those from non-obese healthcare workers. It is a mono-center, prospective cohort study conducted at Franciscus Hospital, where participants will undergo venipuncture to collect blood samples for analysis. The goal is to understand how obesity may influence immune responses and disease severity in COVID-19 patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 65 with a BMI of 30 kg/m² or higher who are patients at Franciscus Hospital.
Not a fit: Patients with acute infections, systemic immunological disorders, or those on immune-modulatory medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how obesity impacts COVID-19 severity, potentially leading to better treatment strategies for affected patients.
How similar studies have performed: Other studies have explored the relationship between obesity and COVID-19 outcomes, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Cohort 1 (obesity cohort) * ≥18 and ≤65 years of age * BMI ≥30 kg/m² * Patient of Franciscus Hospital Cohort 2 (control cohort) * ≥18 and ≤65 years of age * BMI \<25 kg/m² * Healthcare workers of Franciscus Hospital Exclusion Criteria (for both cohorts): * Acute infection or current systemic immunological disorders * Use of immune-modulatory medication (i.e., corticosteroids and biologicals) * Hormonal therapy
Where this trial is running
Rotterdam, South Holland
- Franciscus — Rotterdam, South Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: David S.Y. Ong, M.D., Ph.D., Pharm.D., M.Sc. — Franciscus Hospital
- Study coordinator: Willem A Mak, M.Sc.
- Email: ashwinmak98@gmail.com
- Phone: +316 40897778
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.